Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability

Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the...

Full description

Saved in:
Bibliographic Details
Main Authors: Lee, Donna M. (Author) , Sun, Angela (Author) , Patil, Sneha S. (Author) , Liu, Lijun (Author) , Rao, Aparna V. (Author) , Trent, Parker T. (Author) , Ali, Areej A. (Author) , Liu, Catherine (Author) , Rausch, Jessica L. (Author) , Presutti, Laura D. (Author) , Kaczorowski, Adam (Author) , Schneider, Felix (Author) , Amankulor, Nduka M. (Author) , Shuda, Masahiro (Author) , Duensing, Anette (Author)
Format: Article (Journal)
Language:English
Published: 18 May 2022
In: Scientific reports
Year: 2022, Volume: 12, Pages: 1-10
ISSN:2045-2322
DOI:10.1038/s41598-022-12000-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41598-022-12000-2
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41598-022-12000-2
Get full text
Author Notes:Donna M. Lee, Angela Sun, Sneha S. Patil, Lijun Liu, Aparna V. Rao, Parker T. Trent, Areej A. Ali, Catherine Liu, Jessica L. Rausch, Laura D. Presutti, Adam Kaczorowski, Felix Schneider, Nduka M. Amankulor, Masahiro Shuda & Anette Duensing

MARC

LEADER 00000caa a2200000 c 4500
001 1807752186
003 DE-627
005 20220820204224.0
007 cr uuu---uuuuu
008 220624s2022 xx |||||o 00| ||eng c
024 7 |a 10.1038/s41598-022-12000-2  |2 doi 
035 |a (DE-627)1807752186 
035 |a (DE-599)KXP1807752186 
035 |a (OCoLC)1341461361 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Lee, Donna M.  |e VerfasserIn  |0 (DE-588)1260759903  |0 (DE-627)1807757153  |4 aut 
245 1 0 |a Targeting the translational machinery in gastrointestinal stromal tumors (GIST)  |b a new therapeutic vulnerability  |c Donna M. Lee, Angela Sun, Sneha S. Patil, Lijun Liu, Aparna V. Rao, Parker T. Trent, Areej A. Ali, Catherine Liu, Jessica L. Rausch, Laura D. Presutti, Adam Kaczorowski, Felix Schneider, Nduka M. Amankulor, Masahiro Shuda & Anette Duensing 
264 1 |c 18 May 2022 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 24.06.2022 
520 |a Although KIT-mutant GISTs can be effectively treated with tyrosine kinase inhibitors (TKIs), many patients develop resistance to imatinib mesylate (IM) as well as the FDA-approved later-line agents sunitinib, regorafenib and ripretinib. Resistance mechanisms mainly involve secondary mutations in the KIT receptor tyrosine kinase gene indicating continued dependency on the KIT signaling pathway. The fact that the type of secondary mutation confers either sensitivity or resistance towards TKIs and the notion that secondary mutations exhibit intra- and intertumoral heterogeneity complicates the optimal choice of treatment in the imatinib-resistant setting. Therefore, new strategies that target KIT independently of its underlying mutations are urgently needed. Homoharringtonine (HHT) is a first-in-class inhibitor of protein biosynthesis and is FDA-approved for the treatment of chronic myeloid leukemia (CML) that is resistant to at least two TKIs. HHT has also shown activity in KIT-mutant mastocytosis models, which are intrinsically resistant to imatinib and most other TKIs. We hypothesized that HHT could be effective in GIST through downregulation of KIT expression and subsequent decrease of KIT activation and downstream signaling. Testing several GIST cell line models, HHT led to a significant reduction in nascent protein synthesis and was highly effective in the nanomolar range in IM-sensitive and IM-resistant GIST cell lines. HHT treatment resulted in a rapid and complete abolishment of KIT expression and activation, while KIT mRNA levels were minimally affected. The response to HHT involved induction of apoptosis as well as cell cycle arrest. The antitumor activity of HHT was confirmed in a GIST xenograft model. Taken together, inhibition of protein biosynthesis is a promising strategy to overcome TKI resistance in GIST. 
650 4 |a Cancer 
650 4 |a Cancer therapy 
650 4 |a Oncogenes 
650 4 |a Preclinical research 
650 4 |a Sarcoma 
650 4 |a Targeted therapies 
650 4 |a Translational research 
700 1 |a Sun, Angela  |e VerfasserIn  |4 aut 
700 1 |a Patil, Sneha S.  |e VerfasserIn  |4 aut 
700 1 |a Liu, Lijun  |e VerfasserIn  |4 aut 
700 1 |a Rao, Aparna V.  |e VerfasserIn  |4 aut 
700 1 |a Trent, Parker T.  |e VerfasserIn  |4 aut 
700 1 |a Ali, Areej A.  |e VerfasserIn  |4 aut 
700 1 |a Liu, Catherine  |e VerfasserIn  |4 aut 
700 1 |a Rausch, Jessica L.  |e VerfasserIn  |4 aut 
700 1 |a Presutti, Laura D.  |e VerfasserIn  |4 aut 
700 1 |a Kaczorowski, Adam  |e VerfasserIn  |0 (DE-588)1062747550  |0 (DE-627)806827742  |0 (DE-576)420146318  |4 aut 
700 1 |a Schneider, Felix  |e VerfasserIn  |0 (DE-588)1261900014  |0 (DE-627)180928953X  |4 aut 
700 1 |a Amankulor, Nduka M.  |e VerfasserIn  |4 aut 
700 1 |a Shuda, Masahiro  |e VerfasserIn  |4 aut 
700 1 |a Duensing, Anette  |e VerfasserIn  |0 (DE-588)1186091703  |0 (DE-627)1665366486  |4 aut 
773 0 8 |i Enthalten in  |t Scientific reports  |d [London] : Springer Nature, 2011  |g 12(2022), Artikel-ID 8275, Seite 1-10  |h Online-Ressource  |w (DE-627)663366712  |w (DE-600)2615211-3  |w (DE-576)346641179  |x 2045-2322  |7 nnas  |a Targeting the translational machinery in gastrointestinal stromal tumors (GIST) a new therapeutic vulnerability 
773 1 8 |g volume:12  |g year:2022  |g elocationid:8275  |g pages:1-10  |g extent:10  |a Targeting the translational machinery in gastrointestinal stromal tumors (GIST) a new therapeutic vulnerability 
856 4 0 |u https://doi.org/10.1038/s41598-022-12000-2  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/s41598-022-12000-2  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220624 
993 |a Article 
994 |a 2022 
998 |g 1186091703  |a Duensing, Anette  |m 1186091703:Duensing, Anette  |d 910000  |d 910200  |e 910000PD1186091703  |e 910200PD1186091703  |k 0/910000/  |k 1/910000/910200/  |p 15  |y j 
998 |g 1261900014  |a Schneider, Felix  |m 1261900014:Schneider, Felix  |d 910000  |d 910200  |e 910000PS1261900014  |e 910200PS1261900014  |k 0/910000/  |k 1/910000/910200/  |p 12 
998 |g 1062747550  |a Kaczorowski, Adam  |m 1062747550:Kaczorowski, Adam  |d 910000  |d 910200  |e 910000PK1062747550  |e 910200PK1062747550  |k 0/910000/  |k 1/910000/910200/  |p 11 
999 |a KXP-PPN1807752186  |e 4156207781 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 24.06.2022"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1807752186","language":["eng"],"title":[{"title_sort":"Targeting the translational machinery in gastrointestinal stromal tumors (GIST)","subtitle":"a new therapeutic vulnerability","title":"Targeting the translational machinery in gastrointestinal stromal tumors (GIST)"}],"person":[{"family":"Lee","given":"Donna M.","roleDisplay":"VerfasserIn","display":"Lee, Donna M.","role":"aut"},{"family":"Sun","given":"Angela","roleDisplay":"VerfasserIn","display":"Sun, Angela","role":"aut"},{"family":"Patil","given":"Sneha S.","display":"Patil, Sneha S.","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Lijun","family":"Liu","role":"aut","display":"Liu, Lijun","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Rao, Aparna V.","given":"Aparna V.","family":"Rao"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Trent, Parker T.","given":"Parker T.","family":"Trent"},{"display":"Ali, Areej A.","roleDisplay":"VerfasserIn","role":"aut","family":"Ali","given":"Areej A."},{"family":"Liu","given":"Catherine","roleDisplay":"VerfasserIn","display":"Liu, Catherine","role":"aut"},{"display":"Rausch, Jessica L.","roleDisplay":"VerfasserIn","role":"aut","family":"Rausch","given":"Jessica L."},{"family":"Presutti","given":"Laura D.","roleDisplay":"VerfasserIn","display":"Presutti, Laura D.","role":"aut"},{"family":"Kaczorowski","given":"Adam","display":"Kaczorowski, Adam","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Schneider, Felix","roleDisplay":"VerfasserIn","given":"Felix","family":"Schneider"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Amankulor, Nduka M.","given":"Nduka M.","family":"Amankulor"},{"given":"Masahiro","family":"Shuda","role":"aut","roleDisplay":"VerfasserIn","display":"Shuda, Masahiro"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Duensing, Anette","given":"Anette","family":"Duensing"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"origin":[{"publisherPlace":"[London] ; London","dateIssuedKey":"2011","publisher":"Springer Nature ; Nature Publishing Group","dateIssuedDisp":"2011-"}],"id":{"issn":["2045-2322"],"eki":["663366712"],"zdb":["2615211-3"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Scientific reports","title_sort":"Scientific reports"}],"disp":"Targeting the translational machinery in gastrointestinal stromal tumors (GIST) a new therapeutic vulnerabilityScientific reports","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 12.07.24"],"recId":"663366712","language":["eng"],"pubHistory":["1, article number 1 (2011)-"],"part":{"extent":"10","text":"12(2022), Artikel-ID 8275, Seite 1-10","volume":"12","pages":"1-10","year":"2022"}}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"18 May 2022"}],"id":{"doi":["10.1038/s41598-022-12000-2"],"eki":["1807752186"]},"name":{"displayForm":["Donna M. Lee, Angela Sun, Sneha S. Patil, Lijun Liu, Aparna V. Rao, Parker T. Trent, Areej A. Ali, Catherine Liu, Jessica L. Rausch, Laura D. Presutti, Adam Kaczorowski, Felix Schneider, Nduka M. Amankulor, Masahiro Shuda & Anette Duensing"]}} 
SRT |a LEEDONNAMSTARGETINGT1820